Epinephrine is a Small Molecule owned by Viatris, and is involved in 3 clinical trials, which were completed.
Epinephrine acts directly on alpha-adrenergic receptors and to a lesser degree, beta-adrenergic receptors. Through direct action on alpha1-adrenergic receptors in the mucosa of the respiratory tract, it produces vasoconstriction. It relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors.
The revenue for Epinephrine is expected to reach a total of $5.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Epinephrine NPV Report.
Epinephrine is currently owned by Viatris.
Epinephrine (Epipen/ Fastjekt/ Altellus/ Adrenaline/ Epipen E Z Pen/ Epi E Z Pen JR/ Epipen Jr/ Glaucon) is a sympathomimetic hormone from the adrenal medulla. It is formulated as solution for intramuscular or subcutaneous route of administration and drops solution for ophthalmic route of administration. Epinephrine is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects as order hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects as triatoma, mosquitoes, allergen immunotherapy, foods, drugs, diagnostic testing substances as radiocontrast media and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.
Viatris is a healthcare company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory, cardiovascular, central nervous system (CNS) system and allergy, skin disease, and cancer. It also offers anti-retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries. Viatris is headquartered in Canonsburg, Pennsylvania, the US.
The company reported revenues of (US Dollars) US$17,886.3 million for the fiscal year ended December 2021 (FY2021), an increase of 49.7% over FY2020. The operating loss of the company was US$42 million in FY2021, compared to an operating loss of US$227.6 million in FY2020. The net loss of the company was US$1,269.1 million in FY2021, compared to a net loss of US$669.9 million in FY2020. The company reported revenues of US$4,078.2 million for the third quarter ended September 2022, a decrease of 0.9% over the previous quarter.
Quick View – Epinephrine
|Highest Development Stage|